



EASL

EUROPEAN
ASSOCIATION
FOR THE STUDY
OF THE LIVER

THE INTERNATIONAL LIVER CONGRESS™ 2012

47th ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

Including sessions by the International
Association for the Study of the Liver (IASL)

BARCELONA . SPAIN

APRIL 18 - 22 / 2012

2nd ANNOUNCEMENT AND CALL FOR PAPERS

www.easl.eu/liver-congress

Deadline for receipt of abstracts: **November 23, 2011**



Join EASL on Facebook
www.easl.eu/fb



Follow EASL on Twitter
www.easl.eu/twitter





Caring and curing

At Novartis, we are committed to saving and improving millions of lives...every day.

Breakthrough medicines are our highest priority – they open up healthcare's frontier and answer unmet needs. But no two patients are exactly alike. That's why at Novartis we go beyond breakthrough medicines to offer disease prevention, generic alternatives and access to medicines.

ORGANISED BY:



EASL Office

7 rue des Battoirs
CH-1205 Geneva, Switzerland
Tel: +41 (0)22 807 03 60
Fax: +41 (0)22 328 07 24
easloffice@easloffice.eu
www.easl.eu

ORGANISING SECRETARIAT

KENES INTERNATIONAL

1-3 rue de Chantepoulet, PO Box 1726
CH-1211 Geneva, Switzerland
Tel: +41 (0)22 908 04 88
Fax: +41 (0)22 906 91 40
ilc2012@easl.eu
www.easl.eu/liver-congress

IMPORTANT DATES

ABSTRACTS

Deadline for receipt of abstracts	November 23, 2011
Deadline for receipt of late-breaking abstracts (Submissions only from February 20 – 27, 2012)	February 27, 2012

REGISTRATION

Deadline for early registration	February 20, 2012
Full refund less Euro 35 handling fee	Postmarked prior to February 20, 2012
No Refund	Postmarked from February 21, 2012

AVAILABLE



VICTRELIS™
boceprevir, MSD™



EASL GOVERNING BOARD

SECRETARY GENERAL

Mark Thursz, London, UK

VICE-SECRETARY

Markus Peck-Radosavljevic, Vienna, Austria

TREASURER

Mauro Bernardi, Bologna, Italy

SCIENTIFIC COMMITTEE

Frank Lammert, Homburg, Germany

Matías A. Avila, Pamplona, Spain

George V. Papatheodoridis, Athens, Greece

Daniele Prati, Lecco, Italy

Tania Roskams, Leuven, Belgium

EDUCATIONAL COUNCILLORS

Jean-Francois Dufour, Bern, Switzerland

Fabien Zoulim, Lyon, France

EU POLICY COUNCILLOR

Dominique-Charles Valla, Paris, France

EASL Office

7 rue des Batoirs
CH-1205 Geneva, Switzerland

Tel: +41 (0)22 807 03 60

Fax: +41 (0)22 328 07 24

easloffice@easloffice.eu

www.easl.eu

HONORARY PRESIDENT

Giorgio Verme, Torino, Italy

IASL GOVERNING BOARD

PRESIDENT

Federico Villamil, Buenos Aires, Argentina

PRESIDENT-ELECT

Mario Mondelli, Pavia, Italy

VICE PRESIDENT

Jidong Jia, Beijing, China

SECRETARY-TREASURER

K. Rajender Reddy, Philadelphia, USA



With them all the way

BARACLUDGE® (ENTECAVIR) PRESCRIBING INFORMATION

Consult Summary of Product Characteristics before prescribing and for full list of adverse events

PRESENTATION: Film-coated tablets 0.5 mg or 1 mg entecavir; oral solution 0.05 mg/ml entecavir. **INDICATION:** Chronic Hepatitis B Virus (HBV) Infection in adults with compensated and decompensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase levels and histological evidence of active inflammation and/or fibrosis. **DOSAGE:** Oral. Compensated liver disease *Nucleoside naïve patients:* 0.5 mg OD with or without food. *Lamivudine-refractory patients:* 1 mg OD taken on an empty stomach (>2 hours before or 2 hours after a meal). Decompensated liver disease: 1 mg OD taken on an empty stomach. *Children:* Not recommended for use in children aged under 18 years. *Elderly:* Adjust dose based on renal function. *Renal impairment:* Adjust dose when creatinine clearance <50 ml/min, including haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) patients (see SPC). **CONTRAINDICATIONS:** Hypersensitivity to any ingredient. **WARNINGS AND PRECAUTIONS:** Acute exacerbations of hepatitis when hepatitis B therapy discontinued. If cirrhosis, risk of hepatic decompensation; monitor closely, in particular those with Child-Turcotte-Pugh (CTP) class C disease. Severe exacerbations of hepatitis, including fatalities. Lactic acidosis, sometimes fatal, usually with severe hepatomegaly and hepatic steatosis. Discontinue if rapidly elevating aminotransferase levels, progressive hepatomegaly or metabolic/lactic acidosis occurs. Patients with lamivudine-resistant HBV are at higher risk of developing resistance to entecavir. Virological response should be monitored in

the lamivudine-refractory population and appropriate resistance testing performed. Evaluate renal function in transplant patients receiving cyclosporine or tacrolimus. Entecavir should not be used for HIV/HBV coinfecting patients who are not receiving HAART. Tablets contain lactose; if associated hereditary disorder, use lactose-free oral solution. Oral solution contains maltitol & parahydroxybenzoates (may cause delayed allergic reactions); patients with fructose intolerance should use maltitol-free tablets. **DRUG INTERACTIONS:** Caution with any substance that increases or decreases entecavir concentration. **PREGNANCY AND LACTATION:** Avoid in pregnancy unless clearly necessary. Women of childbearing potential should use effective contraception. Discontinue breastfeeding during treatment with BARACLUDGE®. **UNDESIRABLE EFFECTS:** *Common:* headache, fatigue, dizziness and nausea, insomnia, somnolence, vomiting, diarrhoea, dyspnoea, increased transaminases, laboratory abnormalities e.g. raised ALT (see SPC). *Uncommon:* rash and alopecia. *Rare:* anaphylactoid reaction. **OVERDOSAGE:** Monitor; supportive treatment. **LEGAL CATEGORY:** POM. **AUTHORISATION NUMBERS:** BARACLUDGE® Film Coated Tablets: 0.5 mg (EU/1/06/343/003) for 30 tablets blister pack, 1.0 mg (EU/1/06/343/004) for 30 tablets blister pack. BARACLUDGE® 0.05 mg/ml Oral Solution (EU/1/06/343/005) for 210 ml bottle & graduated measuring spoon. **MARKETING AUTHORISATION HOLDER:** BRISTOL-MYERS SQUIBB PHARMA EELG, Uxbridge Business Park, Sanderson Road, Uxbridge UB81DH, United Kingdom. **DATE OF PI PREPARATION:** July 2011

Adverse events should be reported to Bristol-Myers Squibb Pharmaceuticals Ltd Medical Information on medical.information@bms.com.



First choice for long-term benefits
in NA-naïve patients

Baraclude® is a registered trademark of Bristol-Myers Squibb Company and its affiliates. © 2011 Bristol-Myers Squibb. All rights reserved.

Date of preparation: September 2011

686HQ11PM150
FRBC-K0016 09/11

WELCOME MESSAGE

Dear Colleague,

The International Liver Congress™, 47th annual meeting of the European Association for the Study of the Liver, will take place in Spain from April 18 – 22, 2012 at the Centre Convencions Internacional (CCIB) in Barcelona.

The Convention Centre, designed by prestigious Spanish architect José Luis Mateo, forms part of the new technological and business district in one of the city's best developed urban areas, with a communications and transport network connecting it to the dynamic city of Barcelona. Modern installations and architectural beauty make the CCIB truly unique as one of the largest convention centres in Southern Europe.

Barcelona is not only internationally renowned for its food, culture and hospitality, but moreover is home to some of the most eminent hepatologists in Europe. Hence, we welcome you to join us in Spain for the most important event in the European Hepatology calendar.

The Governing Board of EASL is delighted to host the International Association for Study of the Liver during this International Liver Congress. This will give our meeting a truly global perspective and provide an opportunity for clinicians and researchers from developing countries to present their research and interact with EASL members. There will also be an excellent opportunity for EASL members to get up-to-date with the diagnosis and management of tropical liver diseases at the joint EASL-IASL postgraduate course.

Even in this age of electronic communication, teleconferencing and social networking there is still the need for a major medical congress where medical experts are willing to share their expertise, teaching skills and latest research results with peers. Your presence at the International Liver Congress™ will be a truly worthwhile experience. Undoubtedly, the success of the International Liver Congress™ is due to the enthusiasm and generosity of the scientists and clinicians who attend. We therefore encourage you to participate and contribute to the success of EASL; save the dates in your diary today!



SECRETARY GENERAL OF EASL

Prof. Mark Thursz



VICE-SECRETARY OF EASL

Prof. Markus Peck-Radosavljevic



THE INTERNATIONAL LIVER CONGRESS™ 2012 PRELIMINARY TIMETABLE

Registration desk will open on Tuesday, April 17 between 16:00 –20:00 hours.

Find out more at our booth in the exhibition hall #11

**PLEASE JOIN US FOR
A SATELLITE SYMPOSIUM
THURSDAY, APRIL 19TH, 18:30 – 20:00**

Innovators in the diagnosis and treatment of hepatocellular carcinoma (HCC), Bayer HealthCare Pharmaceuticals brings you two products with a targeted approach to HCC.

Bayer HealthCare Pharmaceuticals is proud to welcome you to Barcelona for the International Liver Congress™, the 47th annual meeting of the European Association for the Study of the Liver.

While at the congress we would like to invite you to attend our satellite symposium, scheduled for Thursday, 19th April 2012, 18:30–20:00 and to visit our booth in the exhibition hall (#11) where you will be able to obtain information on our products and services and to discuss the latest scientific innovations from the company.

We look forward to welcoming you in Barcelona.

	Wednesday, April 18, 2012	Thursday, April 19, 2012	Friday, April 20, 2012	Saturday, April 21, 2012	Sunday, April 22, 2012
07:30-08:00		Industry Sponsored Satellite Symposia	Early Morning Workshops	Early Morning Workshops	
08:00-08:30	EASL-IASL Post Graduate Course	Joint Workshops			
08:30-09:00			General Session 2 & Awards 1	General Session 3 & Awards 2	Major Sponsor Industry Satellite Symposia
09:00-09:30		Post-graduate Course cont.	Basic Science Seminar cont.		
09:30-10:00	Coffee Break				
10:00-10:30	EASL-IASL Post Graduate Course cont.	Joint Workshops	Coffee Break		Coffee Break
10:30-11:00			State of the Art	State of the Art	Symposia (parallel sessions)
11:00-11:30	Coffee Break		Coffee Break	Coffee Break	
11:30-12:00		Post-graduate Course cont.	Basic Science Seminar cont.		
12:00-12:30	Post-graduate Course	Basic Science Seminar	Lunch & Inaugural Poster Session	EU & Impact on General Health	Business Meeting / Posters
12:30-13:00					General Session 4 & Closing
13:00-13:30			Poster / Exhibition & Lunch	Poster / Exhibition & Lunch	
13:30-14:00	Lunch				Farewell Brunch
14:00-14:30			General Session 1 & Opening		Symposia (parallel sessions) 13:30-15:00 YI Forum
14:30-15:00	Post-graduate Course cont.	Basic Science Seminar cont.		Symposia (parallel sessions)	
15:00-15:30				Coffee Break	
15:30-16:00	Coffee Break		Coffee Break	Coffee Break	
16:00-16:30					Parallel Sessions including Late Breaker
16:30-17:00	Post-graduate Course cont.	Basic Science Seminar cont.	Parallel Sessions	Parallel Sessions	
17:00-17:30				Literature Highlights	
17:30-18:00	Coffee Break				
18:00-18:30					Industry Sponsored Satellite Symposia
18:30-19:00	Major Sponsor Industry Satellite Symposia		Major Sponsor Industry Satellite Symposia	Major Sponsor Industry Satellite Symposia	
19:00-19:30					
19:30-20:00					

PRELIMINARY SCIENTIFIC PROGRAMME

Please check the International Liver Congress™ 2012 website for regular updates to the scientific programme (www.easl.eu/liver-congress)

WEDNESDAY, APRIL 18, 2012

08:00-11:00	EASL-IASL Post Graduate Course
08:00-11:00	EASL-IASL POST GRADUATE COURSE PARASITIC LIVER DISEASES/"IMPORTED" LIVER DISEASES
08:00-11:00	Joint Workshops (parallels)
08:00-11:00	EASL-ESPGHAN (European Society for Paediatric Gastroenterology, Hepatology and Nutrition) PAEDIATRIC HEPATOLOGY FOR ADULT HEPATOLOGISTS Co-chairs: D.C. Valla , France A. Dhawan , UK
08:00-11:00	EASL-FLIP (Fatty Liver: Inhibition of Progression) Co-Chairs: F. Lammert , Germany V.D. Ratziu , France
08:00-11:00	EASL-HepaCute & SPHINX Co-Chairs: G. Papatheodoridis , Greece H. Diepolder , Germany M. Albert , France
08:00-11:00	EASL-ILCA (International Liver Cancer Association) Co-Chairs: J.F. Dufour , Switzerland J.M. Llovet , Spain
08:00-11:00	EASL-VIRGIL (European Surveillance Network for Vigilance Against Viral Resistance) NEW ADVANCES IN THERAPY OF CHRONIC VIRAL HEPATITIS Co-Chairs: F. Zoulim , France J.M. Pawlotsky , France
08:00-11:00	EASL-CLIF (Chronic Liver Failure) BACTERIAL INFECTIONS AS A CAUSE OF ACUTE-ON-CHRONIC LIVER FAILURE Co-Chairs: M. Bernardi , Italy P. Gines , Spain

You are cordially invited to attend the satellite symposium at
The International Liver Congress™ by EASL, supported by

Janssen Pharmaceutical Companies of Johnson & Johnson

on **Thursday 19 April 2012, 18:30–20:00**
Centre Convencions Internacional (CC IB)
Barcelona, Spain

MED/HEC/AUC2011/EMA128
Item prepared: January 2012

Janssen Pharmaceutica NV



WEDNESDAY, APRIL 18, 2012, CONTINUED

08:00-11:00	EASL-CHINA NETWORK Co-Chairs: D. Prati , Italy H. Zhuang , China
11:00-11:30	Coffee break
11:30-17:30	Parallel Sessions: POST GRADUATE COURSE / BASIC SCIENCE SEMINAR
11:30-17:30	Post Graduate Course: Alcoholic Liver Disease Organisers: R. Bataller , Spain A. Hadengue , Switzerland F. Zoulim , France
11:30	Introduction A. Hadengue , Switzerland
11:35-12:30	<i>EPIDEMIOLOGICAL AND PUBLIC HEALTH ISSUES</i>
11:35	Q&A Interactive Session: questions
11:40	INCREASING BURDEN OF ALCOHOLIC LIVER DISEASE IN EUROPE H. Cortez-Pinto , Portugal
11:55	CURRENT ACTIONS TO CONFRONT ALCOHOLIC LIVER DISEASE IN EUROPE Nick Sheron , UK
12:10	PATTERNS OF ALCOHOL INTAKE AND ALD: EFFECTS OF BINGE DRINKING ON THE LIVER S. Zakhari , USA
12:25	Q&A Interactive Session: answers
12:35-13:35	<i>NATURAL HISTORY AND MECHANISMS</i>
12:35	Q&A Interactive Session: questions
12:40	NATURAL HISTORY OF ALD: ROLE OF ENVIRONMENTAL AND GENETIC FACTORS F. Stickel , Switzerland
12:55	NOVEL MECHANISMS OF ALCOHOLIC STEATOHEPATITIS S. Lotersztajn , France

13:10	MECHANISMS OF ALCOHOL-INDUCED LIVER FIBROSIS F. Marra , Italy
13:25	Q&A Interactive Session: answers
13:35	Lunch
14:00-15:30	<i>THE PATIENT WITH CHRONIC ALD</i>
14:00	Q&A Interactive Session: clinical case (questions) <i>Fellow: TBC</i>
14:05	HISTOLOGICAL ASSESSMENT OF ALD T. Roskams , Belgium
14:20	NONINVASIVE TOOLS IN THE DIAGNOSIS OF ALD S. Mueller , Germany
14:35	ABUSE OR DEPENDENCE? ASSESSING THE ALCOHOLIC PATIENT IN THE CLINIC A. Gual , Spain
14:50	MANAGEMENT OF ALCOHOL DEPENDENCE IN PATIENTS WITH ALD G. Addolorato , Italy
15:05	EXTRAHEPATIC INVOLVEMENT IN PATIENTS WITH ALD J. Fernández-Solà , Spain
15:20	Q&A Interactive Session: clinical case (answers) A. Louvet , France
15:35-16:00	Coffee Break
16:00-17:30	<i>THE ACUTELY ILL PATIENT</i>
16:00	Q&A Interactive Session: case presentation (questions) <i>Fellow: J.T. Altamirano Gómez</i> , Spain
16:05	MANAGEMENT OF ALCOHOL WITHDRAWAL E.H. Forrest , UK
16:20	ALCOHOLIC HEPATITIS OR DECOMPENSATED CIRRHOSIS: DIAGNOSTIC AND PROGNOSTIC ISSUES F. Nevens , Belgium
16:35	MANAGEMENT OF ALCOHOLIC HEPATITIS A. Hadengue , Switzerland

WEDNESDAY, APRIL 18, 2012, CONTINUED

16:50-17:20	CONTROVERSY: CAN WE OFFER LIVER TRANSPLANTATION TO PATIENTS WITH ALCOHOLIC HEPATITIS?
16:50	YES J-C. Duclos-Vallée , France
17:05	NO J. Neuberger , UK
17:20-17:30	Q&A Interactive Session: case presentation (answers) J. Caballería , Spain
11:30-17:30	Basic Science Seminar: Stem Cells and the Liver Chairs: T. Roskams , Belgium S. Forbes , UK J.F. Dufour , Switzerland
11:30-13:30	<i>SESSION 1: TYPES OF STEM CELLS</i>
11:30	DIFFERENT TYPES OF STEM CELLS AND THEIR POTENTIAL USE C. Verfaillie , Belgium <i>Fellow: L. Ordovas</i> , Belgium
12:00	EMBRYOLOGY OF THE LIVER WITH REFERENCE TO LIVER 'STEM CELLS' F. Lemaigre , Belgium <i>Fellow: A. Poncy</i> , Belgium
12:30	HOW MOUSE GENETICS CAN HELP YOU UNDERSTAND EPITHELIAL STEM CELL BIOLOGY O. Sansom , UK <i>Fellow: TBA</i>
13:00	MULTIPOTENT STEM CELLS IN ADULT EXTRAHEPATIC BILE DUCTS V. Cardinale , Italy <i>Fellow: R. Semeraro</i> , Italy
13:30	Lunch Break

14:00-15:30	<i>SESSION 2: LIVER STEM CELL ACTIVATION AND DIFFERENTIATION</i>
14:00	MOUSE MODELS OF INTRAHEPATIC STEM CELL ACTIVATION S. Forbes , UK <i>Fellow: TBA</i>
14:30	PROGENITOR CELLS IN HUMAN LIVER DISEASE: MECHANISMS OF ACTIVATION AND DIFFERENTIATION T. Roskams , Belgium <i>Fellow: TBA</i>
15:00	CLONALITY STUDIES IN HUMAN LIVER M. Alison , UK <i>Fellow: J.P. Gabriel</i> , UK
15:30-16:00	Coffee Break
16:00-17:30	<i>SESSION 3: LIVER CELL PROLIFERATION AND SENESCENCE: THE YIN AND YANG OF LIVER REGENERATION AND REPAIR</i>
16:00	LIVER REGENERATION AND STEM CELLS F.P. Russo , Italy <i>Fellow: A. Cappon</i> , Italy
16:30	LIVER CELL SENESCENCE: MECHANISMS AND CONSEQUENCES K.L. Rudolph , Germany <i>Fellow: TBA</i>
17:00	STEM CELLS IN LIVER CANCERS S. Thorgeirsson , USA <i>Fellow: TBA</i>
17:30-18:00	Coffee Break
18:00-19:00	Major Sponsor Industry Satellite Symposia

THURSDAY, APRIL 19, 2012

07:30-08:30	Industry Sponsored Satellite Symposia
08:30-12:00	Parallel Sessions: POST GRADUATE COURSE / BASIC SCIENCE SEMINAR
08:30	Post Graduate Course: Alcoholic Liver Disease Organisers: R. Bataller , Spain A. Hadengue , Switzerland F. Zoulim , France
08:30-10:00	LONG TERM MANAGEMENT OF ALD
08:30	Q&A Interactive Session: case presentation (questions) <i>Fellow:</i> N. Goossens , Switzerland
08:35	ALCOHOL CONSUMPTION AS A CO-FACTOR FOR OTHER LIVER DISEASES H. Seitz , Germany
08:50	HEPATOCELLULAR CARCINOMA: IS IT DIFFERENT IN PATIENTS WITH ALD? T. Decaens , France
09:05	EVALUATION AND SELECTION OF CANDIDATES FOR LIVER TRANSPLANTATION G.P. Pageaux , France
09:20	PATIENTS WITH ALD AND LIVER TRANSPLANTATION: SPECIFIC ISSUES P. Burra , Italy
09:35	Q&A Interactive Session: case presentation (answers) A. De Gottardi , Switzerland
10:00-10:30	Coffee Break
10:30-11:30	FUTURE PROSPECTS IN ALD
10:30	NOVEL TARGETS FOR THERAPY IDENTIFIED IN TRANSLATIONAL STUDIES B. Gao , USA
10:45	STEM CELLS IN ALD: THE ROAD FROM ANIMAL MODELS TO HUMAN STUDIES L. Spahr , Switzerland
11:00	CURRENT POLICIES TO DECREASE THE HARM DONE BY ALCOHOL IN EUROPE P. Anderson , The Netherlands
11:15	ILLEGALLY PRODUCED SPIRITS IN EASTERN EUROPE: TO WHAT EXTENT AND AT WHAT RISK? D.W. Lachenmeier , Germany

11:30	PRESENTATION OF THE EASL CLINICAL PRACTICAL GUIDELINES ON ALCOHOLIC LIVER DISEASE P. Mathurin , France
11:55	Concluding Remarks R. Bataller , Spain
08:30-11:30	Basic Science Seminar: Stem Cells and the Liver (contd.) Chairs: T. Roskams , Belgium S. Forbes , UK J.F. Dufour , Switzerland
SESSION 4: STEM CELL THERAPY	
08:30	HEPATOCTE CELL THERAPY M. Ott , Germany <i>Fellow:</i> T. Cantz , Germany
09:00	THE PRODUCTION AND USE OF ES AND IPSC DERIVED HEPATOCYTES L. Vallier , UK <i>Fellow:</i> TBA
09:30	MESENCHYMAL STEM CELL THERAPY AND THE LIVER B. Christ , Germany <i>Fellow:</i> TBA
10:00-10:30	Coffee Break
10:30	TARGETING LIVER CANCER STEM CELLS X.W. Wang , USA <i>Fellow:</i> J. Ji , USA
11:00	INDUCTION OF FUNCTIONAL HEPATOCYTES FROM MOUSE FIBROBLASTS A. Suzuki , Japan <i>Fellow:</i> TBA
11:30	Closing Remarks
12:00-13:30	Lunch and Inaugural Poster Session
12:00-13:30	EU and Impact on General Health European Public Health Chairs: D.C. Valla , France M. Peck , Austria
13:30-15:30	General Session 1 & Opening
15:30-16:00	Coffee Break
16:00-18:00	Parallel Sessions
18:00-18:30	Break
18:30-20:00	Major Sponsor Industry Satellite Symposia

FRIDAY, APRIL 20, 2012

07:30-08:30

Early Morning Workshops (x12 parallels)

- Renal failure in acutely ill cirrhotic patients
- Management of autoimmune hepatitis
- Controversies in alcoholic liver disease
- Do we need liver biopsy in NAFLD?
- Liver regeneration
- Virus-host interactions in hepatitis C
- Treatment of non-1 genotype
- HCV NS5A & NS5B Inhibitors
- HBsAg quantification
- Post-transplant viral hepatitis
- Management of post-transplant biliary disorders
- Which patients with HCC benefit from tyrosine kinase inhibitors?

08:30-10:30

General Session 2 & Awards 1

10:30-11:00

J.P. Benhamou State-of-the-Art Session**ASSESSMENT OF CHRONIC LIVER DISEASE****M. Pinzani**, Italy

11:00-11:30

Coffee Break

11:30-12:30

GRAND ROUNDS PARALLEL SESSIONS & YI SEMINAR

11:30-12:30

Clinical Grand Round 1: **Cholestatic Liver Disease (Norway)**Chair: **K.M. Boberg**, Norway

External Experts:

M.P. Manns, GermanyPresenter: **A. Bergquist**, SwedenPresenter: **C. Schramm**, Germany

11:30-12:30

Clinical Grand Round 2: **Liver Tumours (Germany)**Chair: **P.R. Galle**, Germany

Surgical Commentator: TBC

Pathological Commentator: **P. Schirmacher**, GermanyPresenter: **M. Schuchmann**, GermanyPresenter: **M.A. Wörns**, Germany

11:30-12:30

Clinical Grand Round 3: **Viral Hepatitis (Italy)**Chair: **M. Rizzetto**, Italy

11:30-12:30

Clinical Grand Round 4: **Liver Transplantation (UK)**Chair: **John G. O'Grady**, UK

11:30-12:30

Basic Grand Round 5: **Imaging Techniques in Liver Cell Biology**Chair: **S. van Ijzendoorn**, The Netherlands

11:30-11:40

IMAGING TECHNIQUES IN LIVER CELL BIOLOGY - INTRODUCTION TO THE BASIC GRAND ROUND

S. van Ijzendoorn, The Netherlands

11:40-12:05

ADVANCED CONFOCAL LASER MICROSCOPY AND ENDOSCOPIC IMAGING TECHNIQUES FOR THE STUDY OF THE LIVER

M.H. Nathanson, USA

12:05-12:30

INTRAVITAL IMAGING IN THE LIVER

J. van Rheenen, The Netherlands

11:30-12:30

YI Seminar**EXPERIMENTAL MODELS IN HEPATOLOGY: CLARIFYING AETIO-
PATHOGENESIS IN SEARCHING FOR THERAPEUTIC TARGETS**

11:30

Introduction

11:35

EXPERIMENTAL MODELS OF NAFLD

Q. Anstee, UK

11:50

EXPERIMENTAL MODELS OF CHOLESTATIC LIVER INJURY

M. Trauner, Germany

12:05

EXPERIMENTAL MODELS OF LIVER CANCER

TBC

12:20

Questions & Answers

12:30-14:00

Posters / Exhibition and Lunch

FRIDAY, APRIL 20, 2012, CONTINUED

14:00-15:30

EASL Symposia (parallel sessions)

14:00-15:30

Basic: HCC CELLS: METABOLIC REWIRING AND INTERACTION WITH THE ENVIRONMENTChair: **M.A. Avila**, Spain

Introduction - AN ALTERNATIVE LOOK AT THE HCC CELLS AND THEIR SURROUNDINGS

M.A. Avila, Spain

CANCER CELL METABOLISM. POTENTIAL SITES FOR THERAPEUTIC INTERVENTIONS

J.A. Cuezva, Spain

THE TUMOUR MICROENVIRONMENT IN HCC

L. Roberts, USA

SIGNALS BETWEEN CANCER CELLS AND THE TUMOUR STROMA

G. Giannelli, Italy

14:00-15:30

Clinical: LIVER TRANSPLANTATION FOR RARE DISEASESChair: **J. Belghiti**, France

LT FOR POLYCYSTIC LIVER DISEASE

J. Belghiti, France

LT FOR HEPATOBLASTOMA IN CHILDREN

A. Dhawan, UK

LT FOR HEMANGIOENDOTHELIOMA

J. Lerut, Belgium

LT FOR ENDOENDOCRINE LIVER METASTASES

Y.P. Le Treut, France

14:00-15:30

Clinical: BURDEN AND COST OF LIVER DISEASE IN EUROPEChair: **S. Bellentani**, Italy

Introduction

S. Bellentani, Italy

ALCOHOLIC STEATOHEPATITIS, NON-ALCOHOLIC STEATOHEPATITIS, AND CRYPTOGENIC CIRRHOSIS

H. Cortez-Pinto, Portugal

CHRONIC VIRAL HEPATITIS AND VIRAL CIRRHOSIS

P. Burra, Italy

HEPATOCELLULAR CARCINOMA (HCC)

J. Bruix, Spain

EPIDEMIOLOGY AND COST OF CHRONIC LIVER DISEASE IN EUROPE: PAST, PRESENT AND FUTURE

P. Jepsen, Denmark

14:00-15:30

Clinical: THE EMERGENCE OF THE OMNIPRESENT HEPATITIS E VIRUSChair: **V. Mallet**, France

HEV – STRUCTURE AND REPLICATION

E. Nicand, France

EPIDEMIOLOGY OF HEV - CONTRASTING IN DEVELOPED AND DEVELOPING COUNTRIES

H. Dalton, UK

HEV IN IMMUNOCOMPROMISED PATIENTS

J.M. Peron, France

HEV VACCINE: WHERE ARE WE?

R. Aggarwal, India

15:30-16:00

Coffee Break

16:00-18:00

Parallel Sessions (including Literature session)

16:00-17:00

Recent highlights from the Literature: Ask the Authors!Chair: **U. Beuers**, The Netherlands

18:00-18:30

Break

18:30-20:00

Major Sponsor Industry Satellite Symposia

SATURDAY, APRIL 21, 2012

07:30-08:30	Early Morning Workshops (x12 parallels) <ul style="list-style-type: none"> • Management of ascites • Non cirrhotic portal hypertension • Obesity and the liver • Virus host interactions in hepatitis B • Molecular mechanisms in hepatocarcinogenesis • Side effects of protease inhibitor based therapy • Long term management issues in chronic hepatitis B • Treatment of hepatitis Delta • Timing of transplantation for sclerosing cholangitis • Interim Therapy for HCC • Resection versus transplantation for HCC
08:30-10:30	General Session 3 & Awards 2
10:30-11:00	State-of-the-Art (Basic Science) FROM BASIC RESEARCH TO IMPROVED ANTIBIOTICS A. Yonath , Israel
11:00-11:30	Coffee Break
11:30-12:30	EASL Business Meeting / Posters
12:30-13:30	Posters / Exhibition and Lunch
13:30-15:00	<i>EASL Symposia Parallel sessions & YI Forum</i>
13:30-15:00	EASL Symposia (parallel sessions)
13:30-15:00	Basic: HEPATITIS C IN 2012: MOLECULAR VIROLOGY AND ANTIVIRAL TARGETS Chair: D. Moradpour , Switzerland THE HCV CYCLE: ACHIEVEMENTS AND CHALLENGES C. Rice , USA STRUCTURAL BIOLOGY OF HCV: LESSONS LEARNED AND TERRITORIES TO BE EXPLORED F. Penin , France HCV DRUG DEVELOPEMENT IN 2012: WHAT'S HOT, WHAT'S NOT R. de Francesco , Italy Summary and conclusions D. Moradpour , Switzerland

13:30-15:00	Clinical: CHOLANGIOCARCINOMA AND MIXED LIVER CANCERS Chair: D. Alvaro , Italy EPIDEMIOLOGY OF CHOLANGIOCARCINOMA: INCREASING BURDEN OF CLASSIFICATION D. Alvaro , Italy NEW INSIGHTS IN PATHOLOGY AND MOLECULAR BIOLOGY: A NEED TO STANDARDIZE CURRENT TUMOUR CLASSIFICATION? T. Roskams , Belgium NON-SURGICAL TREATMENT OF CHOLANGIOCARCINOMA S.D. Taylor-Robinson , UK SURGICAL MANAGEMENT OF CHOLANGIOCARCINOMA F. Giuliante , Italy
13:30-15:00	Clinical: GROWING UP WITH LIVER DISEASE Chair: D. Cassiman , Belgium Introduction D. Cassiman , Belgium WHAT THE ADULT HEPATOLOGIST SHOULD KNOW ABOUT PEDIATRIC HEPATOLOGY D. Debray , France A PRACTICAL EXAMPLE OF TRANSITION FROM THE CF CLINIC TBC TRANSITION OF THE TRANSPLANTED PATIENT A. Watson , UK
13:30-15:00	Clinical: HBV IN SPECIAL POPULATIONS Chair: H.L.A. Janssen , The Netherlands HBV IN ACUTE LIVER FAILURE AND DECOMPENSATED DISEASE: WHEN TO TREAT AND WHICH ANTIVIRAL TO USE? A. Lok , USA HBV IN THE SETTING OF IMPAIRED IMMUNITY: WHEN TO USE ANTIVIRAL THERAPY? H. Wedemeyer , Germany HBV IN PREGNANCY: TREAT THE CHILD, THE MOTHER OR BOTH? H.L.A. Janssen , The Netherlands
13:30-14:30	EASL & IASL Joint Symposium Global Public Health Burden: Impact of viral hepatitis
13:30-15:00	YI Forum
15:00-15:30	Coffee Break
15:30-17:30	Parallel Sessions including Late-Breaker
17:30-18:00	Break
18:00-19:00	Industry Sponsored Satellite Symposia

SUNDAY, APRIL 22, 2012

08:30-10:00	Major Sponsor Industry Satellite Symposia
10:00-10:30	Coffee Break
10:30-11:30	<i>EASL Symposia (parallel sessions)</i>
10:30-11:30	<p>Basic: TARGETING SIGNALING PATHWAYS IN HCC: LESSONS LEARNED FROM CLINICAL STUDIES AND ANIMAL MODELS Chair: T. Luedde, Germany</p> <p>BEYOND SORAFENIB: NOVEL AGENTS ON THE HORIZON A.X. Zhu, USA</p> <p>NF-KB: A DOUBLE-EDGED SWORD IN HEPATOCARCINOGENESIS T. Luedde, Germany</p> <p>LYMPHOTOXIN: A NEW DRUG TARGET IN VIRAL HEPATITIS AND HEPATOCELLULAR CARCINOMA M. Heikenwälder, Germany</p>
10:30-11:30	<p>Clinical: ACUTE ON CHRONIC LIVER FAILURE Chair: P. Ginès, Spain</p> <p>DETERMINING THE PROGNOSIS IN ACUTE-ON-CHRONIC LIVER FAILURE R. Moreau, France</p> <p>TREATMENT STRATEGIES FOR ACUTE-ON CHRONIC LIVER DISEASE P. Ginès, Spain</p>
10:30-11:30	<p>Clinical: CHALLENGES IN USING NOVEL PROTEASE INHIBITORS Chair: G.M. Dusheiko, UK</p> <p>Introduction G.M. Dusheiko, UK</p> <p>THE FIRST YEAR: EVIDENCE FROM THE FRENCH NATIONAL ACCESS PROGRAMME L. Serfaty, France</p> <p>RESISTANCE: MEETING THE CHALLENGE a- Telaprevir b- Boceprevir C. Sarrazin, Germany</p>
11:30-13:00	General Session 4 & Closing
13:00-14:00	Farewell Brunch

INDUSTRY SPONSORED
SATELLITE SYMPOSIA

SPONSORS' SYMPOSIA (Preliminary list)

Thursday, April 19, 2012

07:30 – 08:30 - Satellite Symposia organised by:

Abbott
Merz
Sirtex

Saturday, April 21, 2012

18:00 – 19:00 – Satellite Symposia organised by:

BMS – HCC

MAJOR SPONSORS' SYMPOSIA

Wednesday, April 18, 2012

18:00 – 19:30 – Satellite Symposia organised by:

Gilead
F. Hoffmann-La Roche

Thursday, April 19, 2012

18:30 – 20:00 – Satellite Symposia organised by:

Janssen Pharmaceuticals
Bayer

Friday, April 20, 2012

18:30 - 20:00 - Satellite Symposia organised by:

Boehringer Ingelheim
MSD

Sunday, April 22, 2012

08:30 – 10:00 – Satellite Symposia organised by:

Novartis
BMS

ABSTRACT INFORMATION

INTRODUCTION:

- Participants are invited to submit abstracts under any of the categories listed below.
- All accepted abstracts will be published in an abstract book supplement to the Journal of Hepatology.
- Abstracts will be selected by the Scientific Committee for oral or poster presentation. Please indicate your preference in the space provided when submitting your abstract.
- **The deadline for submission of abstracts is November 23, 2011**
- **The deadline for late breaking abstracts is February 27, 2012.**
The website will be re-opened, between February 20–27, 2012 for LATE-BREAKING ABSTRACTS ONLY.
- Should you wish to amend an abstract after submission please contact the Secretariat at ilc2012@easl.eu Amendments received after November 30 will not be accepted.

CATEGORIES

- Liver transplantation / surgery:
 - Experimental
 - Clinical
 - Acute liver failure – clinical & experimental
- Cirrhosis and its complications:
 - Pathophysiology
 - Clinical aspects
 - Bleeding
 - Hepatorinal syndrome and ascites
- Liver tumours:
 - Experimental
 - Clinical (epidemiology, diagnosis)
 - Management
- Molecular and cellular biology:
 - Cell cycle control / apoptosis
 - Biliary tract pathophysiology
 - HSCs and fibrosis
 - Liver regeneration
- Liver Immunology including Viral Hepatitis
- Non-invasive markers of liver fibrosis
- Viral Hepatitis B & D:
 - Experimental
 - Clinical (except therapy)
 - Clinical (therapy, new compounds, resistance)
- Viral Hepatitis C:
 - Experimental (virology)
 - Clinical (except therapy)
 - Clinical (therapy)
 - Clinical (new compounds, resistance)

- Viral Hepatitis A and E
- Fatty Liver Disease:
 - Experimental
 - Clinical
- Alcoholic liver disease and drug induced liver disease
- Autoimmune and chronic cholestatic liver diseases
- Genetic and pediatric liver diseases
- EU Public Health

* **Special category:** IASL Global Health

* IASL Global Health

EASL is pleased to announce that this year at the International Liver Congress™, the International Association for the Study of the liver (IASL) will hold an **EASL-IASL joint Post-Graduate Course and symposium**. In addition, IASL will also hold a parallel session entitled **IASL Global Health and a dedicated poster session**. This initiative has been developed in partnership between our two societies in order to address hepatology in developing countries such as the Middle East, Africa, South/Latin America and some Eastern countries.

Anyone can apply, there are no restrictions. The procedure for abstract submission to the IASL Global Health special category is identical to abstract submission to the International Liver Congress™. Please ensure to select the *Special category IASL Global Health category at the bottom of the TOPICS list on the online abstract submission system. Deadline dates can be found in the "introduction" section above. The rules and guidelines for abstract submission for both the IASL Global Health and International Liver Congress™ can be found on www.easl.eu/liver-congress

Rules for submission of abstracts to the International Liver Congress™ 2012:

- Abstracts that have been presented in previous International Gastroenterology/Hepatology meetings are **NOT accepted**.

WARNING: Please ensure that your abstract has never been presented before.

If this rule is not respected, the abstract will be rejected and will not be considered for the International Liver Congress™.

- ABSTRACTS ARE TO BE SUBMITTED VIA THE CONGRESS WEBSITE ONLY:
www.easl.eu/liver-congress

Please follow the instructions listed on the website step-by-step.

Disclosure

Disclosure of financial relationship, that the author(s) may have with any manufacturer/supplier of any commercial products or services related to the work, must be indicated in the appropriate box on the abstract page on the website.

Disclosures will be included in the printed version of the abstracts.

ABSTRACTS SUBMITTED BY FAX OR E-MAIL WILL NOT BE ACCEPTED.

Retraction and deletion of abstracts

If necessary, Authors may delete a submitted abstract, but only before the abstract submission deadline of November 23, 2011.

Once the deadline date is over all submitted abstracts will be reviewed and accepted abstracts will be published. After the abstract deadline, the authors will have to provide a retraction letter should they wish to retract their abstract.

EASL ABSTRACTS EMBARGO POLICY

Registered congress participants and EASL members will be given individual special access to all abstracts for viewing online approximately 4 weeks prior to the International Liver Congress™ 2012.

Those entitled to view the abstracts prior to the congress will be informed via the email address provided at the time of registration.

Data from abstracts and posters accepted for the International Liver Congress™ 2012 are under media embargo until the date and time of their presentation at the official scientific sessions (Time zone GMT+1).

Media coverage of abstracts being presented at the International Liver Congress™ and industry press releases must not be issued under any circumstances until the individual embargo for each data set lifts.

Accepted Late-Breaker poster presentations will be under embargo from release until AFTER the Inaugural Poster Session on Thursday, April 19, 2012.

Accepted Late-Breaker oral presentations will be under embargo from release until AFTER the Late-Breaker Session on Saturday, April 21, 2012.

Journalists, industry, investigators and/or study sponsors must abide by the embargo times set by EASL. Violation of the embargo will be taken seriously. Individuals and/or sponsors who violate EASL's embargo policies may face sanctions relating to current and future abstract submissions, presentations and visibility at EASL Congresses. The EASL Governing Board is at liberty to ban attendance and/or retract data.

Copyright for abstracts (both oral and poster) on the website and as made available during The International Liver Congress™ 2012 resides with the respective authors. No reproduction, re-use or transcription for any commercial purpose or use of the content is permitted without the written permission of the authors. Permission for re-use must be obtained directly from the author.

DATA SELECTED FOR MEDIA PUBLICATION

All data submitted as part of the scientific sessions will also be considered for media presentation unless otherwise specified by the author.

- **Authors should inform the organisers if they do not wish for their abstract to be considered for selection by the EASL press office.**
- **Authors will be informed following the abstract selection whether the data will also be put forward for media presentation. Authors are responsible for communicating with industry sponsors if their data is selected for media presentation.**

Speakers must declare any "conflict of interest" to the organisers if their data is selected for presentation as part of the International Liver Congress™ official press activities.

EASL YOUNG INVESTIGATORS' BURSARIES

EASL's aim is to support Young Investigators and help them attend the International Liver Congress™ 2012.

In order to achieve the above, EASL offers 2 types of bursaries to the **presenting authors only** of the best accepted abstracts who are aged 35 or under and are still in training.

The application is available to anyone fulfilling the above criteria, without geographical restrictions!

FULL BURSARIES

200 bursaries of **650 Euros** each will be attributed to the presenting author of the best 200 scored abstracts. This bursary will be handed out by cheque during the International Liver Congress™ 2012. In addition, the registration fees to the congress will be waived.

REGISTRATION BURSARIES

Presenting authors of the remaining best accepted abstracts answering the same criteria as mentioned above will have their registration fees waived.

All Bursary Recipients will receive one year free membership to EASL!

APPLICATION INSTRUCTIONS

- Bursary requests can only be made via the abstract form during the on line abstract submission. **Requests received after abstract submissions will not be considered.**
- The name of the presenting author **MUST** match the name of the applicant.
Note! Proof of age (clear copy of ID indicating date of birth) and proof of trainee status (letter signed by head of department) are to be uploaded as either BMP or GIF or JPEG documents, via the Bursary Information page on the EASL website, **after abstract submission but not later than November 30, 2011.** (www.easl.eu/liver-congress)

Any queries relating to bursaries should be sent to: ilc2012@easl.eu

DEADLINE FOR RECEIPT OF DOCUMENTS: NOVEMBER 30, 2011

- **EASL will automatically decline all bursary requests that do not conform to the above terms.**
- Confirmations of the type of bursary granted will be sent out by **February 6, 2012**
- **Confirmed bursary applicants will automatically be registered to the congress (No payment of registration fees is required)**
- **Name changes of presenting authors** (different than at the time of the abstract submission) will be accepted only if made at the time of the submission of the proof documentation.

EASL is willing to assist certain participants with an accepted paper, from resource-limited countries, who encounter financial difficulties to attend the International Liver Congress™ 2012. Further details can be obtained by contacting the EASL Office, IN WRITING ONLY, after the abstract selection has been officially announced.

IMPORTANT NOTE: EASL will grant the above bursaries only to those presenting authors who will attest that they are not being sponsored or financially covered by any other source in order to attend The International Liver Congress™ 2012.

REGISTRATION

Participants may register on-line via the congress website at www.easl.eu/liver-congress

Registration Fees (Inclusive of 8% VAT)

Fees apply to payments received prior to the indicated deadlines.

	Until February 20, 2012	From February 21, 2012 until March 21, 2012	From March 22, 2012 & On-Site
EASL Member *	Euro 100	Euro 150	Euro 300
IASL Member	Euro 100	Euro 150	Euro 300
Non Member	Euro 650	Euro 710	Euro 770
Young Investigator EASL Member */**	Euro 50	Euro 100	Euro 200
Young Investigator **	Euro 150	Euro 200	Euro 250
Nurse***	Euro 150	Euro 200	Euro 250

Wednesday, April 18, 2012

EASL JOINT WORKSHOPS

(one may be chosen)

08:00-11:00

Included in registration fee.

- EASL-CLIF
- EASL-ESPGHAN
- EASL-FLIP
- EASL-HepaCute & SPHINX
- EASL-ILCA
- EASL-VIRGIL
- EASL – China Network

EARLY MORNING WORKSHOPS (one per day may be chosen) Pre-registration for workshops is mandatory. NOTE: Each workshop is limited to a maximum of 60 participants and will be available on a first-come first-served basis.	Friday, April 20, 2012 (12 parallel)	Euro 20
	Saturday, April 21, 2012 (11 parallel)	Euro 20

* Only ACTIVE EASL Members are entitled to the EASL Members' registration fees. Participants who become **NEW EASL Members** after **January 1, 2012**, will be entitled to all EASL membership benefits **excluding** the 'EASL Member' Registration fees for the International Liver Congress™. EASL is a society composed of individual members.

** Under 35 and in training. Proof of age and status must be sent with registration to the Organising Secretariat. (Not part of bursary programme).

*** Proof of nurse status is mandatory. Relevant documentation must be sent with registration to the Organising Secretariat

REGISTRATION FEES FOR PARTICIPANTS INCLUDE:

Admission to the scientific sessions
 Participation in the Post Graduate Course and the Basic Science Seminar: April 18 & 19, 2012
 Participant's bag with congress material
 Coffee breaks and lunches
 Welcome Reception

METHODS OF REGISTRATION:

Registration can be made:

On line: www.easl.eu/liver-congress

By email or fax: Please download and complete the registration form on the website in capital letters and return it to: reg_ilc2012@easl.eu

FOR GROUP REGISTRATIONS

(10 persons or more), please refer to the group registration information on the EASL congress website at: www.easl.eu/liver-congress or contact the registration manager, Mrs Olga Volodarsky at: reg_ilc2012@easl.eu

PAYMENT INSTRUCTIONS:

Please refer to the website www.easl.eu/liver-congress

HOTEL ACCOMMODATION

Kenes International
 Accommodation Department
 1-3 rue de Chantepoulet, PO Box 1726
 CH-1211 Geneva 1, Switzerland
 Tel: +41 22 908 0488
 Fax: +41 22 906 9140
 Email: reg_ilc2012@easl.eu

Kenes International is the official agent for the **International Liver Congress™ 2012 – 47th annual meeting of the European Association for the Study of the Liver.**

Detailed information about the official congress hotels, special reduced room rates, cancellation policies and access to the on-line accommodation form, will be available on the congress website at: www.easl.eu/liver-congress under the Accommodation menu tab.

For **group accommodation** bookings (10 rooms or more), please contact the accommodation manager, Mrs Rachel Gavrieli at: reg_ilc2012@easl.eu

GENERAL CONGRESS INFORMATION

VENUE

Centre Convencions Internacional Barcelona (CCIB), known locally as the 'FORUM'
Avinguda Diagonal 1
08019 Barcelona, Spain
www.ccib.es

LANGUAGE

The official language of the congress is English. Simultaneous translation will not be provided.

CLIMATE

The average daytime temperature in Barcelona in April ranges between 14°C - 20°C. Usually sunny to partly cloudy, though occasional drizzle is possible.

CERTIFICATE OF ATTENDANCE

Certificates of attendance will be available for all participants.

LIABILITY AND INSURANCE

The organiser is not able to take any responsibility whatsoever for injury or damage involving persons and property during the congress. Participants are advised to take out their own personal travel and health insurance for their trip.

OFFICIAL LETTER OF INVITATION

A personal letter of invitation may be downloaded from the EASL congress website (www.easl.eu/liver-congress). Alternatively, upon request, the Congress Secretariat will send a personal invitation. This invitation is meant only to assist participants to raise travel funds or to obtain a visa and is not a commitment on the part of the organisers to provide any financial support. **Applications for invitation letters must be received at least 6 weeks prior to the congress.**

VISA REQUIREMENTS

Participants are requested to check with the Spanish consulate in their home country or with their travel agency for visa requirements. It is the responsibility of the participant to obtain a visa in advance if required.

FOOD AND BEVERAGES

Business lunches and coffee/tea during breaks (as indicated in the programme), are included in the registration fee.

CME ACCREDITATION

EASL is applying for CME Accreditation of the International Liver Congress™ 2012. Updates regarding the number of CME credits will be posted on the website

www.easl.eu/liver-meeting

EXHIBITION

A commercial and industrial exhibition will take place within the framework of the congress.

SPONSORSHIP & EXHIBITION SALES & LIAISON

Kenes International
1-3 rue de Chantepoulet, PO Box 1726
CH-1211 Geneva, Switzerland
Tel: +41 22 908 0488
Fax: +41 22 906 9140
E-mail: myatsiv@kenes.com

ITALIAN DELEGATES

Please note that Italian organisations wishing to sponsor the participation of Italian doctors should present their applications through our officially appointed agency, TWT srl, who will forward them to the Italian Health Ministry. For detailed information please visit the congress website at: www.easl.eu/liver-congress

ORGANISING SECRETARIAT

KENES INTERNATIONAL

1-3 rue de Chantepoulet, P. O. Box 1726
CH-1211 Geneva, Switzerland
Tel: +41 22 908 0488,
Fax: +41 22 906 9140
E-mail: ilc2012@easl.eu
www.easl.eu/liver-congress





You are cordially invited to the Roche
HCV satellite symposium at:

The International Liver Congress™ 2012 by EASL

Barcelona, Spain, 18–22 April 2012
Centre Convencions Internacional (CC IB)

Wednesday 18 April 2012
18:30–20:00



Giving people with liver disease a chance to flourish.

Gilead Hepatic Health is dedicated to transforming the care of patients with chronic liver disease through the development of leading-edge therapies and innovative services that advance treatment expectations and outcomes.

This commitment is reflected in our participation at
The International Liver Congress™ 2012 by EASL.

Date of preparation: September 2011
174/HQ/11-08/PM/1093
© 2011 Gilead Sciences.





3% of the world's population is infected with hepatitis C

Boehringer Ingelheim has a long history of discovering and developing innovative medications of value to physicians and patients. Our Virology Research Center in Laval, Canada is internationally renowned for scientific excellence. Its scientists identified the first new chemical entity directly targeting the hepatitis C virus (HCV) which was shown in clinical trials to reduce viral loads in patients.

Boehringer Ingelheim continues to be at the forefront of HCV and virological research. We are not only investigating ways to dramatically improve HCV cure rates but also to improve the ease of taking anti-HCV medication and developing interferon-free oral regimens that better address the needs of HCV-infected patients.

www.boehringer-ingelheim.com